Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 14 at 2:00 PM ET

Register Free →
CLEATUS
Get CLEATUS
← Back to NAICS Codes
NAICS Code· 541714

NAICS 541714: Research and Development in Biotechnology (except Nanobiotechnology)

This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development. Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries. Illustrative Examples: Cloning research and experimental development laboratories DNA technologies (e.g., microarrays) research and experimental development laboratories Nucleic acid chemistry research and experimental development laboratories Protein engineering research and experimental development laboratories Recombinant DNA research and experimental development laboratories Cross-References. Establishments primarily engaged in--Show more

NAICS 541714 – Research and Development in Biotechnology (except Nanobiotechnology) encompasses scientific research and development activities focused on applying biological systems, organisms, or cellular processes to develop novel therapeutics, diagnostics, vaccines, and biomanufacturing platforms. This sector supports federal initiatives in precision medicine, infectious disease mitigation, biosecurity, and advanced bioprocessing, often involving recombinant DNA technology, protein engineering, cell line development, and high-throughput screening.

130
Active Contracts
$1.0B
Total Obligations (12mo)
446
Awarded Contracts (12mo)
300
Contractors Awarded (12mo)
1
Median Bidders per Award
-14.5%
YoY Growth

Industry Spending Overview

Federal obligations, top contractors and agencies, and related industry codes for NAICS 541714.

AI Industry Description

NAICS 541714 – Research and Development in Biotechnology (except Nanobiotechnology) encompasses scientific research and development activities focused on applying biological systems, organisms, or cellular processes to develop novel therapeutics, diagnostics, vaccines, and biomanufacturing platforms...

NAICS 541714 – Research and Development in Biotechnology (except Nanobiotechnology) encompasses scientific research and development activities focused on applying biological systems, organisms, or cellular processes to develop novel therapeutics, diagnostics, vaccines, and biomanufacturing platforms. This sector supports federal initiatives in precision medicine, infectious disease mitigation, biosecurity, and advanced bioprocessing, often involving recombinant DNA technology, protein engineering, cell line development, and high-throughput screening. In the government contracting landscape, this NAICS code serves as a critical conduit for translating academic and private-sector biotech innovations into mission-critical public health and defense capabilities, frequently intersecting with biomedical engineering, regulatory science, and clinical trial design. Top contractors in this space include Deloitte Consulting LLP, CFD Research Corporation, and PM Consulting Group LLC, reflecting a mix of large professional services firms and specialized small businesses with deep expertise in biostatistics, bioinformatics, and translational research. These firms often serve as technical integrators, bridging laboratory discoveries with scalable, compliant, and government-ready solutions, particularly in areas requiring FDA-aligned development pathways or defense-relevant biosurveillance capabilities. The Department of Health and Human Services and the Department of Defense are the primary awarding agencies, with HHS funding biomedical innovation through NIH and BARDA programs, while DoD supports biodefense, battlefield medical readiness, and countering biological threats through agencies like DARPA and the U.S. Army Medical Research and Development Command. Demand is driven by pandemic preparedness, medical countermeasure development, and next-generation biothreat detection systems. The competitive landscape is highly technical and innovation-driven, with opportunities concentrated in contract research organizations, specialized R&D services, and government-sponsored translational partnerships. Contractors with proven experience in GMP compliance, biosafety level containment, and federal regulatory submission processes are best positioned to compete in this high-stakes, mission-critical sector.

Small Business Size Standard

The SBA threshold that decides who can bid NAICS 541714 work as a small business.

1,000 employees
Applies to the whole industry code

The SBA cap for this NAICS (13 CFR 121.201). A business at or under it can self-certify as small for work in this code, which is what makes it eligible for a small-business set-aside. The cap is set per NAICS, so the same company can be small in one code and not in another.

13 CFR 121.201, effective January 1, 2026. The SBA revises the table roughly once a year.

Top Contractors

Companies with the highest total award value under NAICS 541714, ranked by dollars won.

Ranked by total awards
CompanyTotal AwardsContracts
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)$263.6M1
SHIONOGI INC.$156.1M1
CHENEGA SERVICES & FEDERAL SOLUTIONS, LLC$72.4M1
CIDARA THERAPEUTICS INC$58.1M1
VERICEL CORPORATION$34.9M1
BATTELLE MEMORIAL INSTITUTE$32.1M9
UNIVERSITY OF MIAMI$28.3M2
UES INC Dayton OH 45432 USA$25.0M1
CHENEGA PROFESSIONAL & TECHNICAL SERVICES LLC$20.6M2
PRENOSIS, INC$20.0M1

Top Agencies

Federal agencies directing the most contract spending toward NAICS 541714.

Department Of Health And Human Services163 awards$716.3M
Defense Health Agency1 award$72.4M
Department Of Defense45 awards$66.1M
Department Of Health And Human Services (hhs)107 awards$53.6M
National Institutes Of Health Nida1 award$26.6M
Department Of Veterans Affairs51 awards$25.8M
FA8650 USAF Afmc Afrl Pzl Afrl/pzl1 award$25.0M
FDA Office Of Acquisitions And Grants Services1 award$16.7M
Army Medical Resources Acq Activity1 award$11.5M
National Aeronautics And Space Administration13 awards$10.8M

Competition

How many companies historically bid on federal awards in NAICS 541714, from bidder counts reported on USAspending.

Usually Single-Bid

Half or more of reported awards drew exactly one bidder, usually a sign of incumbent-held work rather than an open field. · 4,542 reported awards

Median Bidders

1

Per reported award, all-time

Single-Bid Awards

65%

Share of reported awards with one bidder

10+ Bidder Awards

14%

Share of reported awards with 10+ bidders

Reported Awards

4,542

87% of 5,225 total awards

Bidder Count Distribution by Fiscal Year

Share of reported awards in each bidder-count bracket per federal fiscal year.

How this code compares up the NAICS hierarchy. Parent cohorts pool every code under their prefix, so they are the steadier baseline when a 6-digit sample is thin.

Industry FamilyCompetitionMedian BiddersSingle-BidBidder MixReported Awards
541714This Code
Research and Development in Biotechnology (except Nanobiotechnology)
Usually Single-Bid165%
4,54287% of 5,225
54171NAICS Industry
Fewer Bidders242%
246,33582% of 298,788
5417Industry Group
Scientific Research and Development Services
Fewer Bidders240%
282,62484% of 338,309
541Subsector
Fewer Bidders249%
2,918,78285% of 3,416,794
54Sector
Professional, Scientific, and Technical Services
Fewer Bidders249%
2,918,78285% of 3,416,794

Bidder counts reported on past federal awards in this NAICS (USAspending). An open opportunity has no bidders yet, so this is the historical norm for similar work, not a fact about this solicitation. Not all awards report bidder counts, and fewer bidders often means incumbent-held work rather than an easier win. Federal reporting of bidder counts fell from ~96% of awards (FY2016) to ~30% (FY2018 onward); the chart shows shares of reported awards, and washed-out stretches mark years with fewer than 30 of them.

Related NAICS Codes

Industries similar to Research and Development in Biotechnology (except Nanobiotechnology), by shared sector, subsector, and industry group.

Research and Development in Nanotechnology

This U.S. industry comprises establishments primarily engaged in conducting nanotechnology research ...
541713Same Industry GroupHigh Similarity

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

This U.S. industry comprises establishments primarily engaged in conducting research and experimenta...
541715Same Industry GroupHigh Similarity

Research and Development in the Social Sciences and Humanities

This industry comprises establishments primarily engaged in conducting research and analyses in cogn...
541720Same Industry GroupHigh Similarity

Offices of Lawyers

This industry comprises offices of legal practitioners known as lawyers or attorneys (i.e., counselo...
541110Same SubsectorMedium Similarity

Offices of Notaries

This industry comprises establishments (except offices of lawyers and attorneys) primarily engaged i...
541120Same SubsectorMedium Similarity

title Abstract and Settlement Offices

This U.S. industry comprises establishments (except offices of lawyers and attorneys) primarily enga...
541191Same SubsectorMedium Similarity

All Other Legal Services

This U.S. industry comprises establishments of legal practitioners (except offices of lawyers and at...
541199Same SubsectorMedium Similarity

Offices of Certified Public Accountants

This U.S. industry comprises establishments of accountants that are certified to audit the accountin...
541211Same SubsectorMedium Similarity

Explore contracts across multiple NAICS codes Browse all NAICS Codes

Dotted
NAICS 541714 FAQ

Frequently Asked Questions

NAICS code 541714 covers Research and Development in Biotechnology (except Nanobiotechnology). This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development. Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries. Illustrative Examples: Cloning research and experimental development laboratories DNA technologies (e.g., microarrays) research and experimental development laboratories Nucleic acid chemistry research and experimental development laboratories Protein engineering research and experimental development laboratories Recombinant DNA research and experimental development laboratories Cross-References. Establishments primarily engaged in--

Recently Posted in Research and Development in Biotechnology (except Nanobiotechnology)

NAICS: 541714
Awarded
Federal
J&A to extend Period or Performance for procurement of Inmazeb
Solicitation # JOFOC-REG-1
This justification and approval document, identified by solicitation number JOFOC-REG-1, outlines a contract modification with Regeneron Pharmaceuticals Inc. to extend the period of performance for the procurement of Inmazeb. The action involves a total value of 297,715,850.15 dollars for the manufacture and delivery of up to 26,500 doses of the Ebola virus therapeutic for the Strategic National Stockpile. Managed by the Department of Health and Human Services through Barda, the procurement is conducted as an other than full and open competition. This approach is justified under FAR 6.103-1, as Regeneron Pharmaceuticals Inc. is identified as the only responsible source capable of meeting the specific performance standards and FDA BLA licensure requirements for this therapeutic. The contract is associated with NAICS code 541714 and lists the place of performance in New York.
Barda - Aspr / Daappo / Barda Dcma

POSTED

3 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Grant
High-Throughput Functional Genomic AssayingThis subcontract, titled High-Throughput Functional Genomic Assaying, supports National Institutes of Health and NHGRI research projects by providing experimental testing of genomic variants. The scope of work involves implementing high-throughput assays to perturb variants and executing functional interpretation strategies utilizing CRISPR-based systems and high-throughput screening platforms. The selected provider is responsible for delivering raw molecular and cellular data along with all associated metadata. The project is managed under the Department of Health and Human Services and requires strict adherence to 45 CFR Part 46 regulations regarding human subjects research. The opportunity was posted on October 9, 2026, with a response deadline of December 14, 2026. It is categorized under NAICS code 541714 for research and development in biotechnology.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Specialized Phenotypic Assay Development/ExecutionThis subcontract, titled Specialized Phenotypic Assay Development/Execution, supports prime contractors on NIH IGVF Consortium projects under the Department of Health and Human Services. The primary objective is the collection of robust phenotypic data through the execution of imaging, proteomics, and transcriptomics assays designed to measure the impacts of variant interactions. To achieve this, the contractor will utilize advanced technical equipment, including mass spectrometers, flow cytometers, and high-content imaging systems. The scope of work emphasizes the delivery of high-quality phenotypic data sets while adhering to strict quality control standards for high-throughput data. This opportunity falls under NAICS code 541714 and was posted on October 9, 2026, with a response deadline of December 14, 2026.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Senescence-Specific Reagent and Tool ManufacturingThis subcontract, titled Senescence-Specific Reagent and Tool Manufacturing, supports National Institutes of Health projects focused on senescence technologies. The selected provider will develop and supply innovative reagents, biospecimens, and tools for prime contractors, specifically focusing on the creation of markers for phenotypic identifiers and the manufacture of reagents to identify senescence heterogeneity within secretomes and tissue environments. The scope of work requires the use of biotechnology laboratory facilities for antibody production and protein synthesis, with a final delivery of validated assays and physical reagents. All operations must strictly adhere to NIH guidelines regarding human systems. The opportunity was posted on October 9, 2026, with a response deadline of November 23, 2026, falling under NAICS code 541714.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
Solicitation # RFA-RM-27-007
The National Institutes of Health, under the Department of Health and Human Services, is soliciting the development or adaptation of innovative senescence technologies (SenTecs) through solicitation RFA-RM-27-007. These technologies aim to identify, characterize, and understand senescent cell heterogeneity within tissue environments and secretomes to improve strategies for modulating these cells in human aging and disease. The program utilizes a five-year, milestone-driven award structure divided into two phases: a two-year UG3 phase focused on development and feasibility, and a three-year UH3 phase dedicated to optimization, refinement, and validation. Transition to the UH3 phase is not automatic and requires an administrative review at the end of year two. The final year of the award requires a collaborative demonstration project within the SenNet consortium. The NIH intends to commit 5.4 million dollars in total costs for fiscal year 2027 to fund up to nine awards, with direct cost caps of 400,000 dollars per year for the UG3 phase and 550,000 dollars per year for the UH3 phase. Applications are evaluated based on the importance of the research, scientific rigor, feasibility, and the expertise of the investigators. Required submissions include an Intellectual Property Strategy and a Data Management and Sharing Plan. Awardees must adhere to strict cybersecurity incident reporting, maintain a seven-year confidentiality agreement for non-public information, and ensure all technical assets and data are deposited into the SenNet Data Portal. Clinical trials are not allowed under this specific opportunity.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)
Solicitation # RFA-HG-27-008
The National Human Genome Research Institute (NHGRI), under the Department of Health and Human Services, is soliciting applications for the Impact of Genomic Variation on Function (IGVF) Data and Coordinating Center (DACC) via solicitation RFA-HG-27-008. The DACC will serve as the central hub for the IGVF Consortium, tasked with developing a comprehensive, searchable catalog of genomic function and variant impacts and managing a data portal for housing and sharing consortium resources. Key technical objectives include the hardening of data processing pipelines to ensure they are containerized, robust, and reproducible, while adopting existing data and metadata standards to promote interoperability. The NHGRI intends to commit 6 million dollars in total costs for the period of FY 2027-2031, with annual application budgets limited to 4 million dollars in direct costs. Funding decisions are based on scientific peer review and program-specific considerations, focusing on technical merit, synergy with other IGVF projects, and the applicant's capability to coordinate large-scale genomic data efforts. Applicants must maintain active registrations in SAM, eRA Commons, and Grants.gov, and all Principal Investigators must have a linked ORCID ID. Special requirements include a dedicated Project Manager devoting at least 6 person months and strict adherence to the Cybersecurity Act of 2015, which mandates reporting cybersecurity incidents within 48 hours of discovery. Proposals must include a Research Strategy limited to 30 pages and be submitted via an institutional system-to-system solution by the December 14, 2026, deadline.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
Solicitation # RFA-RM-27-016
The National Institutes of Health (NIH) is soliciting applications under RFA-RM-27-016 to establish SenNet Discovery and Validation Centers (DVCs) as part of Stage 2 of the Cellular Senescence Network. The primary objective of these centers is to define, refine, and validate tissue- and disease-relevant cellular senescence signatures, known as senotypes, and their associated biomarkers. DVCs are required to investigate the functional consequences of these signatures in human health and disease, generate high-quality molecular, cellular, and spatial datasets for public release via the Data Coordination and Informatics Center, and execute consortium-wide organizational and outreach activities. The maximum project period is five years, with application budgets limited to approximately 3 million dollars in direct costs per year. A specific requirement includes a mandatory 600,000 dollar annual direct cost allocation for the SenNet Organization and Outreach Component, of which 40 to 45 percent must support educational programs. Additionally, starting in Year 2, centers must set aside approximately 10 percent of their total budget for cross-consortium validation. Applications are evaluated through the NIH peer review system based on significance, approach, and the protection of human subjects, with performance measured annually by the successful acceptance and public release of data. Applicants must maintain active registrations in the System for Award Management and eRA Commons. Required submission materials include a 30-page application divided into four elements covering vision, preclinical modeling, biospecimen management, and outreach, along with letters of support and human subjects documentation where applicable. Awardees must adhere to strict data security protocols, including a seven-year confidentiality disclosure agreement and a requirement to report cybersecurity incidents within 48 hours.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)
Solicitation # RFA-HG-27-007
The National Institutes of Health, through the Department of Health and Human Services, is soliciting applications under RFA-HG-27-007 to establish centers for the Impact of Genomic Variation on Function (IGVF) Consortium. The primary objective is to characterize genomic variation and assess how individual variants in DNA, RNA, or protein-coding elements impact genome function and phenotypes. Funded centers will utilize high-throughput methods to perturb variants, collect molecular and cellular data, and develop portable data processing pipelines. These centers are expected to collaborate within the consortium to coordinate assays and cell types, contributing raw and processed data to the IGVF Catalog via the Data Analysis and Coordination Center. The funding cycle runs from 2027 through fiscal year 2031, with a maximum project period of five years and budgets limited to 2 million dollars in direct costs per year. Notably, 20 percent of direct costs must be allocated to support collaborative work. Applications are evaluated based on scientific merit through the NIH peer review system and a second level of review by the National Advisory Council for Human Genome Research, focusing on significance, overall impact, and the utility of the proposed assays. Clinical trials are not allowed, and research involving human subjects must comply with 45 CFR Part 46. Applicants must maintain active registrations in the System for Award Management and eRA Commons, and all Principal Investigators must have a linked ORCID ID. Required submissions include a Research Strategy limited to 30 pages, a Resource Sharing Plan, and a Data Management and Sharing Plan. Key personnel requirements include a minimum of three person-months of effort for the PD/PI and a dedicated Project Manager committing at least four person-months. Additionally, awardees must implement a cybersecurity incident response plan with a 48-hour notification requirement for any discovered incidents.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials Not Allowed)
Solicitation # RFA-HG-27-009
Solicitation RFA-HG-27-009 is a Notice of Funding Opportunity from the National Institutes of Health, under the Department of Health and Human Services, for a UM1 Research Project with Complex Structure Cooperative Agreement. The program seeks to establish interaction centers to study how genetic or environmental interactions modify genomic variant impact as part of the second phase of the Impact of Genomic Variation on Function (IGVF) Consortium. Awardees must develop a quantitative research framework to detect joint effects beyond additive modifiers, apply genomic perturbation methods to collect phenotypic data, and share all resulting data, analyses, and predictive methods through the IGVF portal and catalog. The initiative is designed as discovery science to improve the understanding of genome-wide association studies and polygenic scores. Eligible applicants include small businesses and other for-profit organizations, with a maximum project period of five years and a budget limit of 1.5 million dollars in direct costs per year. Applications are due by December 14, 2026, and are evaluated via the NIH peer review system based on significance, contribution to consortium goals, and the rigor of the proposed research. Key requirements include a dedicated Project Manager devoting at least four person months and a PD/PI effort of at least three person months. Additionally, awardees must comply with strict cybersecurity incident reporting guidelines, maintain active SAM and eRA Commons registrations, and adhere to federal regulations regarding human subjects and vertebrate animal research.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed)
Solicitation # RFA-HG-27-010
The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications through RFA-HG-27-010 for the Computational Modeling and Analysis of the Impact of Genomic Variation on Function initiative. This UM1 Research Project with Complex Structure Cooperative Agreement seeks to establish centers that will join the Impact of Genomic Variation on Function (IGVF) Consortium. The primary objective is to develop, apply, and test interpretable computational models that utilize biological, biochemical, and biophysical mechanistic information to determine how genomic variation affects genome function and phenotypes related to human health. Awardees are expected to produce open-source software, models, and documentation, while sharing predictions and integrative analyses via the IGVF catalog and data portal. The maximum project period is five years, with application budgets limited to 800,000 dollars in direct costs. A critical requirement is that 20 percent of direct costs must be allocated annually to support collaborative work. Personnel requirements include a minimum aggregate effort of three person months for PD/PIs and a dedicated Project Manager devoting at least four person months. Applications are evaluated via the NIH peer review system based on significance, investigators, innovation, approach, and environment, with a focus on the likelihood of exerting a sustained influence on the research field. Eligible applicants include small businesses and other for-profit organizations, provided they maintain active SAM registration and a Unique Entity Identifier. All awards are administered under 42 CFR Part 52 and 2 CFR Part 200.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
Solicitation # RFA-RM-27-016
The National Institutes of Health is seeking applications for the Cellular Senescence Network Discovery and Validation Centers under solicitation RFA-RM-27-016. This initiative represents Stage 2 of the SenNet program, focusing on the definition, refinement, and validation of tissue- and disease-relevant cellular senescence signatures, known as senotypes, and their associated biomarkers. Selected centers will investigate the functional consequences of these signatures on human health and disease while generating high-quality molecular, cellular, and spatial datasets to be shared with the broader scientific community. Awardees are expected to utilize complementary experimental systems to validate biomarkers and analyze responses to senotherapeutic approaches or senescence-associated perturbations. In addition to research goals, applicants must propose specific aims for consortium-wide organizational and outreach activities. Interested parties must submit their responses by the deadline of November 24, 2026.
Rmod

POSTED

5 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
Solicitation # RFA-RM-27-007
The National Institutes of Health is soliciting proposals for the Cellular Senescence Network through solicitation RFA-RM-27-007 to develop or adapt innovative senescence technologies. These technologies aim to identify, characterize, and understand the biological consequences of senescent cell heterogeneity within tissue environments and secretomes. The ultimate goal is to create novel strategies for modulating these cells in vivo and predicting outcomes for human aging and various disease conditions. These five-year, milestone-driven awards are structured in two distinct phases. The initial two-year UG3 phase focuses on technology development and feasibility, while the subsequent three-year UH3 phase is dedicated to optimization, refinement, and validation, concluding with a collaborative demonstration project within SenNet. Applicants must submit both phases together, though transition to the UH3 phase is contingent upon an administrative review following the second year. Responses are due by November 24, 2026.
Rmod

POSTED

5 days ago

DEADLINE

in about 1 month
View Details

Win Contracts in Research and Development in Biotechnology (except Nanobiotechnology)

Get AI-powered intelligence on NAICS 541714 procurement

Real-time contract opportunities for NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology))

AI-powered matching based on your business capabilities and past performance

Competitive analysis of contractors winning awards in this industry

Automated alerts when new opportunities are posted

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS